U.S. patent application number 13/203523 was filed with the patent office on 2011-12-22 for agent for prevention or amelioration of obesity.
This patent application is currently assigned to HIROSHIMA UNIVERSITY. Invention is credited to Fumiko Higashikawa, Masafumi Noda, Masanori Sugiyama.
Application Number | 20110311502 13/203523 |
Document ID | / |
Family ID | 42665344 |
Filed Date | 2011-12-22 |
United States Patent
Application |
20110311502 |
Kind Code |
A1 |
Sugiyama; Masanori ; et
al. |
December 22, 2011 |
AGENT FOR PREVENTION OR AMELIORATION OF OBESITY
Abstract
To provide a pharmaceutical product or food which has an
excellent fat-accumulation-inhibiting activity and/or
fat-metabolism-improving activity and which is effective for
inhibition or improvement of obesity, fatty liver, etc. The present
invention provides an agent for preventing or ameliorating obesity
containing, as an active ingredient, cells of a lactic acid
bacterium belonging to the genus Pediococcus, a cell culture
thereof, or an extract of any of these.
Inventors: |
Sugiyama; Masanori;
(Hiroshima, JP) ; Higashikawa; Fumiko; (Hiroshima,
JP) ; Noda; Masafumi; (Hiroshima, JP) |
Assignee: |
HIROSHIMA UNIVERSITY
Higashi-Hiroshima-shi
JP
|
Family ID: |
42665344 |
Appl. No.: |
13/203523 |
Filed: |
February 26, 2010 |
PCT Filed: |
February 26, 2010 |
PCT NO: |
PCT/JP2010/001334 |
371 Date: |
August 26, 2011 |
Current U.S.
Class: |
424/93.45 ;
424/780; 435/170; 435/252.1 |
Current CPC
Class: |
A23L 33/135 20160801;
A61K 35/74 20130101; A61P 3/00 20180101; A61P 3/04 20180101; A61P
3/06 20180101; A23V 2002/00 20130101; A23V 2002/00 20130101; A23V
2200/332 20130101; A23V 2200/3204 20130101; A23V 2002/00 20130101;
A23V 2200/30 20130101; A23V 2200/3204 20130101 |
Class at
Publication: |
424/93.45 ;
424/780; 435/252.1; 435/170 |
International
Class: |
A61K 35/74 20060101
A61K035/74; C12N 1/20 20060101 C12N001/20; C12P 1/04 20060101
C12P001/04; A61P 3/04 20060101 A61P003/04 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 27, 2009 |
JP |
2009-046388 |
Claims
1. An agent for preventing or ameliorating obesity containing, as
an active ingredient, cells of a lactic acid bacterium belonging to
the genus Pediococcus, a cell culture thereof, or an extract of any
of these.
2. A fat-accumulation-inhibiting agent containing, as an active
ingredient, cells of a lactic acid bacterium belonging to the genus
Pediococcus, a cell culture thereof, or an extract of any of
these.
3. A fat-metabolism-improving agent containing, as an active
ingredient, cells of a lactic acid bacterium belonging to the genus
Pediococcus, a cell culture thereof, or an extract of any of
these.
4. A food for preventing or ameliorating obesity containing cells
of a lactic acid bacterium belonging to the genus Pediococcus, a
cell culture thereof, or an extract of any of these.
5. The agent for preventing or ameliorating obesity according to
claim 1, the fat-accumulation-inhibiting agent according to claim
2, the fat-metabolism-improving agent according to claim 3, or the
food according to claim 4, wherein the lactic acid bacterium
belonging to the genus Pediococcus is Pediococcus pentosaceus LP28
strain, which has been deposited as NITE ABP-700 at the National
Institute of Technology and Evaluation, Patent Microorganisms
Depositary.
6. Pediococcus pentosaceus LP28 strain, which has been deposited as
NITE ABP-700 at the National Institute of Technology and
Evaluation, Patent Microorganisms Depositary.
7. Use of cells of a lactic acid bacterium belonging to the genus
Pediococcus, a cell culture thereof, or an extract of any of these,
for producing an agent for preventing or ameliorating obesity.
8. Use of cells of a lactic acid bacterium belonging to the genus
Pediococcus, a cell culture thereof, or an extract of any of these,
for producing a fat-accumulation-inhibiting agent.
9. Use of cells of a lactic acid bacterium belonging to the genus
Pediococcus, a cell culture thereof, or an extract of any of these,
for producing a fat-metabolism-improving agent.
10. A method for preventing or ameliorating obesity, characterized
in that the method comprises administering, to a subject in need
thereof, cells of a lactic acid bacterium belonging to the genus
Pediococcus, a cell culture thereof, or an extract of any of these,
or allowing a subject in need thereof to consume cells of a lactic
acid bacterium belonging to the genus Pediococcus, a cell culture
thereof, or an extract of any of these.
Description
TECHNICAL FIELD
[0001] The present invention relates to an agent for preventing or
ameliorating obesity containing, as an active ingredient, cells of
a lactic acid bacterium, a culture thereof, etc. and to products
related thereto.
BACKGROUND ART
[0002] Obesity is defined as a condition in which energy sources
such as carbohydrates and lipids have been over-accumulated as
neutral fat in white adipocytes which are present in the living
tissue, particularly in the subcutaneous adipose tissue or in the
organ-peripheral tissue, resulting in an increase in body weight
beyond the limits of skeletal systems or physiological functions.
Among fat tissues, a visceral fat tissue, which builds up around an
internal organ such as the mesentery, is thought to trigger
abnormality in metabolism of carbohydrate or lipid, possibly
resulting in lifestyle-related diseases such as heart diseases,
arteriosclerosis, hypertension, diabetes, and fatty liver. When the
aforementioned visceral-fat-induced obesity is associated with a
plurality of arteriosclerosis risk factors including diabetes
(carbohydrate metabolic disorder), hyperlipidemia (lipid metabolic
disorder), and hypertension, such a condition is called metabolic
syndrome. In metabolic syndrome, even when individual symptoms are
not so severe, combination of a plurality of symptoms
synergistically elevate possibility of onset of lifestyle-related
diseases. Thus, metabolic syndrome patients are categorized into a
high-risk group, and prevention and therapy of metabolic syndrome
have been focused on.
[0003] As described above, accumulation of visceral fat is thought
to be a considerably important factor for the onset of metabolic
syndrome, lipid metabolic disorders (e.g., fatty liver and
hyperlipidemia), carbohydrate metabolic disorders (e.g., diabetes),
and cardiovascular diseases such as heart infarction and brain
infarction. Therefore, for preventing or ameliorating these disease
and pathological conditions, it is important to reduce accumulation
of visceral fat.
[0004] Measures that have been proposed for preventing obesity
include control of metabolism of lipid taken into the body,
promoting burning of body fat, intake of a food or supplement which
inhibits accumulation of fat, and administration of an anti-obesity
agent in the medical field have been proposed. However, currently,
there is only a few means to be effective for preventing and
ameliorating obesity, from the aspect of safety and practical
utility (e.g., satisfactory taste or processability).
[0005] Meanwhile, lactic acid bacteria have been used for many
years in production of food, particularly milk products such as
fermented milk, lactic acid bacterium beverage, and fermented
butter. In addition, since lactic acid bacteria themselves have a
variety of pharmacological activities including intestinal function
control action, the lactic acid bacteria are used as materials for
producing health food products, pharmaceutical products, etc. In
previous reports of activity of lactic acid bacteria on fat
accumulation, those belonging to genus Lactobacillus or the genus
Lactococcus have been found to have a visceral-fat-reducing
activity (Patent Document 1), and those belonging to the genus
Lactobacillus gasseri have been found to have a
fatty-liver-inhibitory action (Patent Document 2).
[0006] However, a lactic acid bacterium belonging to the genus
Pediococcus has never been known to have a
fat-accumulation-inhibiting activity and/or a
fat-metabolism-improving activity.
PRIOR ART DOCUMENTS
Patent Documents
[0007] Patent Document 1: JP-A-2008-214253 [0008] Patent Document
2: JP-A-2008-24680
SUMMARY OF THE INVENTION
Problems to be Solved by the Invention
[0009] An object of the present invention is to provide a
pharmaceutical product or food which has an excellent
fat-accumulation-inhibitory action and/or fat-metabolism-improving
action and which is effective for inhibition or improvement of
obesity, fatty liver, etc.
Means for Solving the Problems
[0010] The present inventors have carried out extensive studies on
the pharmacological activity of lactic acid bacteria, and have
found that lactic acid bacteria belonging to the genus Pediococcus
have a fat-accumulation-inhibitory action and a
lipid-metabolic-disorder-improving activity. The present invention
has been accomplished on the basis of this finding.
[0011] Accordingly, the present invention is directed to the
following (1) to (10):
[0012] (1) an agent for preventing or ameliorating obesity
containing, as an active ingredient, cells of a lactic acid
bacterium belonging to the genus Pediococcus, a cell culture
thereof, or an extract of any of these;
[0013] (2) a fat-accumulation-inhibiting agent containing, as an
active ingredient, cells of a lactic acid bacterium belonging to
the genus Pediococcus, a cell culture thereof, or an extract of any
of these;
[0014] (3) a fat-metabolism-improving agent containing, as an
active ingredient, cells of a lactic acid bacterium belonging to
the genus Pediococcus, a cell culture thereof, or an extract of any
of these;
[0015] (4) a food for preventing or ameliorating obesity containing
cells of a lactic acid bacterium belonging to the genus
Pediococcus, a cell culture thereof, or an extract of any of
these;
[0016] (5) an agent for preventing or ameliorating obesity
according to (1), a fat-accumulation-inhibiting agent according to
(2), a fat-metabolism-improving agent according to (3), or a food
according to (4), wherein the lactic acid bacterium belonging to
the genus Pediococcus is Pediococcus pentosaceus LP28 strain, which
has been deposited as NITE ABP-700 at the National Institute of
Technology and Evaluation, Patent Microorganisms Depositary;
[0017] (6) Pediococcus pentosaceus LP28 strain, which has been
deposited as NITE ABP-700 at the National Institute of Technology
and Evaluation, Patent Microorganisms Depositary;
[0018] (7) use of cells of a lactic acid bacterium belonging to the
genus Pediococcus, a cell culture thereof, or an extract of any of
these, for producing an agent for preventing or ameliorating
obesity;
[0019] (8) use of cells of a lactic acid bacterium belonging to the
genus Pediococcus, a cell culture thereof, or an extract of any of
these, for producing a fat-accumulation-inhibiting agent;
[0020] (9) use of cells of a lactic acid bacterium belonging to the
genus Pediococcus, a cell culture thereof, or an extract of any of
these, for producing a fat-metabolism-improving agent; and
[0021] (10) a method for preventing or ameliorating obesity,
characterized in that the method comprises administering, to a
subject in need thereof, cells of a lactic acid bacterium belonging
to the genus Pediococcus, a cell culture thereof, or an extract of
any of these, or allowing a subject in need thereof to consume
cells of a lactic acid bacterium belonging to the genus
Pediococcus, a cell culture thereof, or an extract of any of
these.
Effects of the Invention
[0022] The agent for preventing or ameliorating obesity,
fat-accumulation-inhibiting agent, and fat-metabolism-improving
agent according to the present invention can be used as a
pharmaceutical product, a food, etc. for preventing, treating, or
ameliorating lipid metabolic disorders (e.g., fatty liver and
hyperlipidemia), carbohydrate metabolic disorders (e.g., diabetes),
and cardiovascular diseases such as heart infarction and brain
infarction. In addition, the lactic acid bacterium belonging to the
genus Pediococcus can be provided on a large scale at low cost, has
high safety, and can be administered for a long period of time.
Thus, the lactic acid bacterium of the present invention is
remarkably useful.
BRIEF DESCRIPTION OF THE DRAWINGS
[0023] FIG. 1: A graph showing body weight change profiles under
intake of high-fat food.
[0024] FIG. 2: A graph showing the weights of white adipocytes
under intake of high-fat food.
[0025] FIG. 3: A graph showing the liver neutral fat (triglyceride)
levels under intake of high-fat food.
MODES FOR CARRYING OUT THE INVENTION
[0026] The lactic acid bacterium employed in the agent of the
present invention for preventing or ameliorating obesity is a
lactic acid bacterium belonging to the genus Pediococcus.
[0027] No particular limitation is imposed on the lactic acid
bacterium belonging to the genus Pediococcus, so long as the lactic
acid bacterium exhibits the effects of the present invention.
Examples of the lactic acid bacterium of the present invention
include Pediococcus pentosaceus Pediococcus damnosus, Pediococcus
urinaeequi, Pediococcus cerevisiae, and Pediococcus halophilus.
Among such bacteria, preferred is a lactic acid bacterium belonging
to the genus Pediococcus which exhibits high viability in the human
intestinal tract and, in food products produced therefrom, which
exhibits high percent survival and provides excellent flavor and
texture.
[0028] Among them, Pediococcus pentosaceus is more preferred.
Pediococcus pentosaceus LP28 strain, which has been deposited as
NITE ABP-700 (Date of original deposit: Jan. 27, 2009) at the
National Institute of Technology and Evaluation, Patent
Microorganisms Depositary (2-5-8, Kazusakamatari, Kisarazu City,
Chiba 292-0818 JAPAN), is even more preferred.
[0029] The LP28 strain has been first isolated from the fruit of
Longan by the present inventors. The nucleotide sequence of 16S
rDNA of the LP28 strain has a homology of 99.5% to that of
Pediococcus pentosaceus ATCC 25745 strain (DDBJ/GenBank/EMBL
ID=FM179610). The LP28 strains exhibits a tetragena profile under
microscope after Gram staining. Therefore, the LP28 strain has been
identified as Pediococcus pentosaceus. The LP28 strain has the
following general mycological characteristics:
[0030] (1) Gram-positive lactococcus, (2) homo-type lactic
fermentation, 3) catalase negative, (4) no endospore formability,
(5) culturable under aerobic conditions, and (6) producing
exopolysaccharide.
[0031] In the present invention, cells of the lactic acid bacterium
which have been recovered by culturing the bacterium through a
customary method for cultivating a lactic acid bacterium and
separating cells thereof from the culture by cell-collecting means
such as centrifugation may be used without performing further
treatment. Alternatively, a culture/fermentation liquid (culture
supernatant), a concentration thereof, or a cytoplasm fraction or a
cell wall fraction obtained through treatment of cells of the
bacterium with an enzyme or by physical means, may also be used.
The cells may be viable cells or killed cells.
[0032] No particular limitation is imposed on the medium in which
the lactic acid bacterium of the present invention is cultured, and
there may be employed a variety of media such as a fruit juice
medium, a vegetable juice medium, a milk medium, a skimmed milk
medium, a medium containing a milk component, and a semi-synthetic
medium free of a milk component. Specific examples of the culture
medium include a reduced skimmed milk medium produced through
heat-sterilized skimmed milk; a skimmed milk medium to which yeast
extract has been added; an MRS medium; and a GAM medium.
[0033] No particular limitation is imposed on the culturing method,
so long as the method allows favorable growth of the target cells.
Examples of the method include stationary culture, neutralization
culture (at a constant pH), batch culture, and continuous
culture.
[0034] In the culturing, sake cake, a distillation residue obtained
in the production of sho-chu, or an extract thereof is preferably
added to the culture medium. Particularly in the case of producing
fermented milk, fermented fruit juice, or fermented vegetable
juice, such an additive is preferably used, since a favorable
fermentation product can be obtained.
[0035] In the present invention, the cells of a lactic acid
bacterium belonging to the genus Pediococcus or the extract of the
cell culture of the bacterium refers to various solvent-extracts
obtained through solvent extraction of cells of the bacterium or
the cell culture thereof, a dilution product thereof, a
concentration product thereof, or a dry powder thereof.
[0036] The extraction solvent for use in recovering the extract of
the present invention may be either a polar solvent, a non-polar
solvent, or a mixture thereof. Examples of the solvent include
water; alcohols such as methanol, ethanol, propanol, and butanol;
polyhydric alcohols such as propylene glycol and butylene glycol;
ketones such as acetone and methyl ethyl ketone; esters such as
methyl acetate and ethyl acetate; linear or cyclic ethers such as
tetrahydrofuran and diethyl ether; polyethers such as polyethylene
glycol; hydrocarbons such as hexane, cyclohexane, and petroleum
ether; aromatic hydrocarbons such as benzene and toluene; and
pyridines. Among them, esters such as ethyl acetate and alcohols
such as ethanol are preferred.
[0037] Extraction conditions vary in accordance with the type of
solvent. In one preferred extraction procedure, a solvent (1 to 10
parts by mass) is used with respect to 1 part by mass of culture
liquid, and extraction is performed at 0 to 50.degree. C.,
preferably 25 to 37.degree. C., for 0.5 hours to 3 hours.
[0038] The aforementioned extract may be used as is.
Alternatively, the extract may be diluted, concentrated, or
lyophilized, and the product may be formed into powder or paste, as
desired. Through a purification technique such as liquid-liquid
partition, the extract may be appropriately purified before
use.
[0039] As described in the Examples hereinbelow, the cells of a
lactic acid bacterium belonging to the genus Pediococcus of the
present invention can inhibit body weight increase in a
hypernutrition state and can reduce the weight of white adipocyte
tissue and the liver neutral fat (triglyceride) level. Thus, cells
of a lactic acid bacterium belonging to the genus Pediococcus, a
cell culture thereof, or an extract of any of these can serve as an
agent for preventing or ameliorating obesity, a
fat-accumulation-inhibiting agent, or a lipid-metabolism-improving
agent. That is, cells of a lactic acid bacterium belonging to the
genus Pediococcus, a cell culture thereof, or an extract of any of
these can be employed as a food, pharmaceutical product, or the
like which can effectively prevent, treat, or ameliorate
pathological conditions triggered by accumulation of body fat
and/or lipid metabolic disorder; i.e., obesity, lipid metabolic
disorders (e.g., fatty liver and hyperlipidemia), and carbohydrate
metabolic disorders (e.g., diabetes), or which can effectively
prevent, treat, or ameliorate cardiovascular diseases such as heart
infarction and brain infarction. When the bacterium is employed for
providing a food, the food may have a product concept of prevention
or amelioration of obesity, a healthy diet, etc. and may serve as a
functional food (e.g., a beauty food, patient diet, or food for
specified health uses) optionally having a label indicating such
effects.
[0040] The agent for preventing or ameliorating obesity,
fat-accumulation-inhibiting agent, or lipid-metabolism-improving
agent of the present invention may be perorally or parenterally
administered as a pharmaceutical product or a supplement. In
peroral administration, a tablet, a capsule, a granule, a powder, a
syrup, etc. may be employed. In parenteral administration, an
injection, a suppository, an inhalation, a percutaneous agent, a
drug for external use, etc. may be employed. In the preparation of
various forms of the aforementioned pharmaceutical preparations and
supplements, additional pharmaceutically acceptable carries may be
appropriately used in combination, so long as the effects of the
bacterial cells or culture of the present invention are not
impaired. Examples of such carriers include a vehicle, a binder, a
bulking agent, a disintegrator, a surfactant, a lubricant, a
dispersant, a buffer, a preservative, a flavoring agent, a perfume,
a coating agent, a carrier, and a diluent.
[0041] Among the administration routes, peroral administration is
preferred. When the bacterium of the present invention is used as a
peroral preparation, the preparation has a fat content of 0.1 mass
% to 100 mass % with respect to the total amount of the
preparation, preferably 1 mass % to 100 mass %.
[0042] The agent for preventing or ameliorating obesity,
fat-accumulation-inhibiting agent, or lipid-metabolism-improving
agent of the present invention may be employed as a variety of food
products. Examples of the form thereof include beverages such as
fruit juice, vegetable juice, sparkling drink, tea beverage, milk
beverage, fermented milk, fermented fruit juice, fermented
vegetable juice, alcoholic beverages, and refreshing beverages;
other foods such as jelly-like foods, snack foods, baked cakes,
cakes, chocolate, jam, bread, gum, candy, soup, pickles, and
tsukuda-ni; and the same as the aforementioned forms in relation to
the peroral preparation (tablet, capsule, syrup, etc.).
[0043] The culture product of the lactic acid bacterium belonging
to the genus Pediococcus of the present invention serves, without
any further treatment, as a fermented food such as yogurt, cheese,
miso, shoyu, or pickles. By use of such fermented milk or cheese as
raw material, bread, snack food, cakes, etc. for the concept of
reducing visceral fat may be provided.
[0044] No particular limitation is imposed on the amount of the
lactic acid bacterium of the present invention incorporated into
the pharmaceutical product or food, and the bacterium content may
be appropriately adjusted in accordance with the daily dose or
other factors. In the case of liquid preparations, the lactic acid
bacterium content is preferably adjusted to 1.times.10.sup.8
cells/mL to 1.times.10.sup.10 cells/mL. In the case of solid
preparations, the bacterium content is preferably adjusted to
1.times.10.sup.8 cells/g to 1.times.10.sup.10 cells/g.
[0045] When viable cells of the lactic acid bacterium of the
present invention belonging to the genus Pediococcus are
administered, the daily dose thereof for an adult is preferably
1.times.10.sup.12 to 5.times.10.sup.13 cfu/day.
[0046] The present invention will next be described in more detail
by way of Examples and Test Examples.
EXAMPLES
Production Example 1
Preparation of Cells of a Lactic Acid Bacterium
[0047] An MRS medium (product of Merck) was sterilized at
118.degree. C. for 15 minutes. To the culture medium, Pediococcus
pentosaceus LP28 strain (deposited as NITE ABP-700 (Date of
original deposit: Jan. 27, 2009) at the National Institute of
Technology and Evaluation, Patent Microorganisms Depositary (2-5-8,
Kazusakamatari, Kisarazu City, Chiba 292-0818 JAPAN) was
inoculated. The thus-inoculated cells were cultured at 28.degree.
C. for 36 hours under anaerobic conditions. The resulting culture
product was washed thrice with PBS and lyophilized, to thereby
recover a cell powder of LP28 strain. The cell powder was stored at
-80.degree. C. before experiments. In a similar manner,
Lactobacillus plantarum SN13T strain (NITE P-7), obtained from
sausage, was cultured, to thereby recover a cell powder of SN13T
strain, as a comparative strain sample.
Test Example 1
(1) Test Method
[0048] A high-fat diet (D12492-Rodent Diet with 60 kcal % Fat,
Research Diets Inc., New Brunswick, N.J.) was fed to 7-week-old to
8-week-old mice (BALB/c) over 6 weeks, to thereby trigger obesity.
In the subsequent 8 weeks, the same high-fat diet was fed to the
mice with or without intake of a cell powder of LP28 strain or a
cell powder of SN13T strain, prepared in Production Example 1. The
body weight of each mouse was monitored. Also, 8 weeks after start
of intake of each bacterium, the weight of white adipose tissue in
the abdominal cavity of each mouse and the amount of liver neutral
fat thereof were measured.
[0049] The amount of liver neutral fat was determined by removing
the liver from the mouse, suspending the liver in
chloroform/methanol (2:1), shaking the suspension, and determining
the triglyceride level of the chloroform layer (Triglyceride E-Test
Wako for triglyceride level determination, product of Wako Pure
Chemical Industries, Ltd.).
[0050] In intake of the cell powder of LP28 strain or the cell
powder of SN13T strain, each cultured product of the cells was
added to a crumbled feed (25 mg/l g-crumbled feed), and mice (5
mice in each group) were allowed to take the chaw ad libitum. No
difference was observed in consumption of the feed among the lactic
acid bacterium-free group, LP28-intake group, and SN13T-intake
group, and the daily consumption was about 2.5 g/mouse.
(2) Results
[0051] In the LP28-intake group, the body weight increase
attributed to intake of the high-fat diet was significantly
inhibited (P<0.05), as compared with the lactic acid
bacterium-free group. In contrast, no difference in body weight was
observed between the SN13T-intake group and the lactic acid
bacterium-free group (FIG. 1). In the LP28-intake group, the white
adipose tissue weight (FIG. 2), the liver weight, and the liver
neutral fat level (FIG. 3) in intake of the high-fat diet were
reduced.
[0052] Thus, since LP28 exhibited effects of inhibiting increases
in body weight and fat and fat liver in a hypernutrition state, the
strain is thought to be effective for preventing or ameliorating
metabolic syndrome.
Test Example 2
Variation in Gene Expression in the Liver
[0053] Among the test animals of Test Example 1, one mouse was
chosen from each of the LP28-intake group and the lactic acid
bacterium-free group, and total RNA was extracted from the liver of
each mouse. The liver sample was subjected to cDNA microarray
analysis (Affymetrix).
[0054] As a result, variation of expression of a variety of
fat-related genes, including very low density lipoprotein receptor,
CD36 antigen, peroxisome proliferator activated receptor gamma
(PPAR.gamma.), stearoyl-coenzyme A desaturase 1, sterol regulatory
element binding transcription factor 1 (SREBF1), and fatty acid
synthase, was observed.
Example 1
Production of Fermented Milk
[0055] Cells of Pediococcus pentosaceus LP28 strain (NITE ABP-700)
were cultivated at 30.degree. C. for 20 hours in a medium
containing 100% from-concentrate pear juice, 1.0% sodium citrate,
and 1.0% sho-chu distillation residue extract, to thereby prepare a
preliminary culture liquid. Separately, 1% sho-chu distillation
residue extract was added to 13% skimmed milk (product of Meiji
Dairies Corporation). The mixture was sterilized at 121.degree. C.
for 15 minutes and then cooled to 30.degree. C., to thereby yield a
main culture medium. The above-produced preliminary culture liquid
was inoculated (2%) to the main culture medium, and cultivation was
performed at 30.degree. C. for 24 hours, to thereby produce
fermented milk (lactic acid acidity: 0.59%).
Example 2
Production of Fermented Vegetable Juice
[0056] Cells of Pediococcus pentosaceus LP28 strain (NITE ABP-700)
were cultivated at 30.degree. C. for 20 hours in a medium
containing 100% from-concentrate pear juice, 1.0% sodium citrate,
and 1.0% sho-chu distillation residue extract, to thereby prepare a
preliminary culture liquid. Separately, 0.1% skimmed milk and 0.8%
sho-chu distillation residue extract were added to 100%
from-concentrate carrot juice. The mixture was sterilized at
105.degree. C. for 5 minutes and then cooled to 30.degree. C., to
thereby yield a carrot juice culture medium. The above-produced
preliminary culture liquid was inoculated (2%) to the carrot juice
culture medium, and cultivation was performed at 30.degree. C. for
24 hours, to thereby produce fermented carrot juice (lactic acid
acidity: 0.61%).
* * * * *